2Eyes Vision, specialist in the creation and development of ophthalmic technologies secures an investment from Bullnet Capital
· The company has developed SimVis, the first technology ever allowing presbyopic and cataract patients to experience the real world through multifocal corrections before intraocular lens implantation, refractive surgery, or contact lens fitting..
· The investment will allow the company to release a first version of the product and start its commercialization.
Madrid, 4th December 2017—2Eyes Vision, spin off of the Visual Optics and Biophotonics Laboratory of the Spanish National Research Council (CSIC) has announced today a Series A investment led by Bullnet Capital. The investment will provide the company with the necessary resources to strengthen product development and to create a sales and marketing structure.
The SimVis technology is the result of a 7 year investigation and it allows cataract and presbyopic patients to experience, for the first time, the real world through multifocal corrections before contact lens fitting and intraocular lenses implantation, allowing the ophthalmologist to take a personalized decision on the lens to be implanted based on the patient’s preferences.
"With several million people affected by these ocular conditions, the impact of SimVis is enormous. The availability of SimVis in the clinic reduces uncertainty both for the clinician and for the patient and decreases the number of patients dissatisfied or with undesired visual phenomena. In addition, from a scientific point of view, SimVis allows to design and validate new corrections that adapt to the needs of patients. Said Dr. Iñigo Jiménez Alfaro, Head of the Ophthalmology Service at Fundación Jiménez Díaz.
In 2015, Carlos Dorronsoro and Susana Marcos, co-inventors of the SimVis technology, promoted the creation of 2Eyes Vision and licensed from CSIC the patents protecting the technology. Since then, 2Eyes Vision, formed by an experienced and multidisciplinary team of engineers, ophthalmologists and optometrists, has proven the potential of the technology. SimVis will be commercially available in 2018 and was officially presented at ESCRS 2017, the largest exhibition of cataract and refractive surgery, that took place between the 7th and the 10th of October in Lisbon. Additionally, the core patent of the technology has been granted as the best patent in the XII edition of the MadrI+D awards.
According to Javier Ulecia from Bullnet Capital “2Eyes Vision is a company completely in line with our investment criteria: a team with proven experience in the technology world with patent-protected products, capable of creating new technologies and to develop an effective commercial strategy at a global level in sectors with growing demand”.
2Eyes Vision S.L